CSF1R and Neurodevelopmental delay: Treatment with PLX5622, a CSF1R inhibitor used in preclinical models to wipe out microglial populations, has been shown to improve metabolic outcomes in mice (Ali et al., 2020), while treatment with GW2580, another CSF1R inhibitor, was associated with prevention of synaptic degeneration and reduced microglial inflammation (Neal et al., 2020), indicating CSF1R inhibition as a potential medium for alleviating neuroinflammation and NDD pathology.